11

March 11, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancer and other metastatic cancers: A pharmaceutical mixture encompassing Olaparib, an FDA-approved poly (adenosine diphosphate-ribose) polymerase inhibitor, and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as RBPMS, RECK, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets ovarian cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 12/March/2019, 12.11 am

Introduction: What they say: A study from the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City (K.M.); University of Milan-Bicocca, European Institute of Oncology […]
March 11, 2019

Repurposing the anti-analgesic agent Celecoxib into an anti-HIV agent: Celecoxib (trade name: Celebrex), a selective cox-2 (Cyclooxygease-2) inhibitor, increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 11/March/2019, 11.46 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the anti-analgesic agent Celecoxib into an anti-HIV agent: Celecoxib (trade name: Celebrex), a selective cox-2 […]